Please assess the completion status of the following clinical trial:

Trial Title: Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed melanoma of the skin: Breslow, Clark, histological type. Location of the primary, clinical, or pathological regional status.~* Complete staging demonstrating the presence of distant metastases, either visceral or in soft tissues or bone tissue: Brain, Lung, Abdomen, and Pelvis CT and bone scintigraphy.~* Objectively measurable disease by clinical or radiological means~* Karnofsky's Performance Status is more significant than 70%~* Life expectancy greater than three months~* Patients over 18 years old~* Informed consent from the patient to participate in the protocol~Exclusion Criteria:~* Age greater than or equal to 65 years~* Ongoing active infections, including viral immunodeficiency~* Previous chemotherapy within less than two months~* Concomitant malignant tumors (e.g., Chronic Lymphocytic Leukemia, etc.)~* Uncontrolled concomitant diseases (Hypertension, unstable Diabetes mellitus, renal diseases requiring dialysis)~* Situations or conditions requiring urgent surgical intervention, such as intestinal obstruction due to metastasis~* Pregnancy or lactation~* Concurrent participation in other therapeutic research protocols~* Any condition that compromises the objectives of this study.~Removal Criteria from the Study:~* By the patient's decision to discontinue the study.~* Intolerable adverse reactions, according to WHO Criteria Grading Toxicities~* Intercurrent illness that may compromise the patient's life or interfere with the treatment study evaluation~* Requirements for concomitant medication that may interfere with study results.~* Failure to complete the study entirely~* Failure to follow up on the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAPCells (Type: EXPERIMENTAL): Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).